{"transactions":[{"id":1207745,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2025-03-13T16:02:02.000Z","date":"2025-03-11","kind":"grant","planned":false,"acquired":true,"shares":758400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option will vest on March 11, 2026 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person."}],"balance_after":2925098,"derivative":{"exercise_price":3.58,"expiration_date":"2035-03-11","underlying":"Common Stock","underlying_shares":758400},"source":{"system":"sec-edgar","filing":"0000950170-25-038694","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000095017025038694/ownership.xml","form_type":"4"}},{"id":1589111,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2024-03-07T18:39:40.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":510000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option will vest on March 7, 2025 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person."}],"balance_after":2170310,"derivative":{"exercise_price":3.51,"expiration_date":"2034-03-07","underlying":"Common Stock","underlying_shares":510000},"source":{"system":"sec-edgar","filing":"0001628280-24-009745","document":"wk-form4_1709854769.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000162828024009745/wk-form4_1709854769.xml","form_type":"4"}},{"id":1950029,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2023-03-16T17:41:38.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":482064,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option will vest on March 15, 2024 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person."}],"balance_after":1664477,"derivative":{"exercise_price":1.72,"expiration_date":"2033-03-15","underlying":"Common Stock","underlying_shares":482064},"source":{"system":"sec-edgar","filing":"0001628280-23-008354","document":"wf-form4_167900288656705.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000162828023008354/wf-form4_167900288656705.xml","form_type":"4"}},{"id":2102446,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-11-29T16:11:12.000Z","date":"2022-11-25","kind":"purchase","acquired":true,"shares":10000,"price":1.43,"value":14300.0,"ownership":{"direct":true},"balance_after":24481,"source":{"system":"sec-edgar","filing":"0001628280-22-030946","document":"wf-form4_166975625707899.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000162828022030946/wf-form4_166975625707899.xml","form_type":"4"}},{"id":2339829,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2022-03-10T18:39:37.000Z","date":"2022-03-09","kind":"grant","acquired":true,"shares":370128,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"92,532 vest on 3/09/2023. 7,711 vest monthly for 36 months beginning on 4/09/2023 through 3/09/2026."}],"balance_after":1185400,"derivative":{"exercise_price":2.5,"expiration_date":"2032-03-09","underlying":"Common Stock","underlying_shares":370128},"source":{"system":"sec-edgar","filing":"0001628280-22-005790","document":"wf-form4_164695553669989.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000162828022005790/wf-form4_164695553669989.xml","form_type":"4"}},{"id":2670192,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2021-06-14T16:11:48.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":435072,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"108,768 vest on 6/10/2022. 9,064 vest monthly for 36 months beginning on 7/10/2022 through 6/10/2025."}],"balance_after":815272,"derivative":{"exercise_price":7.98,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":435072},"source":{"system":"sec-edgar","filing":"0001628280-21-012172","document":"wf-form4_162370149350115.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000162828021012172/wf-form4_162370149350115.xml","form_type":"4"}},{"id":2774834,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-03-23T12:24:00.000Z","date":"2021-03-23","kind":"purchase","acquired":true,"shares":965,"price":10.3417,"value":9979.7405,"ownership":{"direct":true},"balance_after":14481,"source":{"system":"sec-edgar","filing":"0001628280-21-005335","document":"wf-form4_161651662768276.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000162828021005335/wf-form4_161651662768276.xml","form_type":"4"}},{"id":2920592,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2021-01-05T16:03:27.000Z","date":"2021-01-02","kind":"exercise","acquired":false,"shares":260,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit is the economic equivalent of one share of Cardiff Oncology, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 4, 2017, the reporting person was granted 1,459 restricted stock units, 260 of which vested on January 2, 2021. The common stock into which such vested restricted stock units converted on January 2, 2021 is reported in Table I on this Form 4."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 4, 2017, the reporting person was granted 1,459 restricted stock units, 260 of which vested on January 2, 2021. The common stock into which such vested restricted stock units converted on January 2, 2021 is reported in Table I on this Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":260},"source":{"system":"sec-edgar","filing":"0001628280-21-000060","document":"wf-form4_160988059527289.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000162828021000060/wf-form4_160988059527289.xml","form_type":"4"}},{"id":2920591,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-01-05T16:03:27.000Z","date":"2021-01-02","kind":"tax_withholding","acquired":false,"shares":113,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting person is reporting the withholding by Cardiff Oncology, Inc. of 113 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 4, 2021."}],"balance_after":13516,"source":{"system":"sec-edgar","filing":"0001628280-21-000060","document":"wf-form4_160988059527289.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000162828021000060/wf-form4_160988059527289.xml","form_type":"4"}},{"id":2920590,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-01-05T16:03:27.000Z","date":"2021-01-02","kind":"exercise","acquired":true,"shares":260,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the conversion upon vesting of restricted stock units into common stock (the \"Converted Common Stock\"). On January 4, 2017, the reporting person was granted 1,459 restricted stock units, 261 of which vested on January 2, 2020. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 4, 2017."}],"balance_after":13629,"source":{"system":"sec-edgar","filing":"0001628280-21-000060","document":"wf-form4_160988059527289.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000162828021000060/wf-form4_160988059527289.xml","form_type":"4"}},{"id":3104331,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2020-06-19T16:15:49.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":221241,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"73,747 vest on each of 6/17/2021, 2022 and 2023."}],"balance_after":380200,"derivative":{"exercise_price":2.6,"expiration_date":"2030-06-17","underlying":"Common Stock","underlying_shares":221241},"source":{"system":"sec-edgar","filing":"0001104659-20-075234","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000110465920075234/a4.xml","form_type":"4"}},{"id":3145577,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-05-18T16:17:27.000Z","date":"2020-05-14","kind":"purchase","acquired":true,"shares":6993,"price":1.43,"value":9999.99,"ownership":{"direct":true},"balance_after":13369,"source":{"system":"sec-edgar","filing":"0001104659-20-063184","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000110465920063184/a4.xml","form_type":"4"}},{"id":3323235,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2020-01-03T16:15:33.000Z","date":"2020-01-02","kind":"exercise","acquired":false,"shares":261,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 4, 2017, the reporting person was granted 1,459 restricted stock units, 261 of which vested on January 2, 2020. The common stock into which such vested restricted stock units converted on January 2, 2020 is reported in Table I on this Form 4."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 4, 2017, the reporting person was granted 1,459 restricted stock units, 261 of which vested on January 2, 2020. The common stock into which such vested restricted stock units converted on January 2, 2020 is reported in Table I on this Form 4."}],"balance_after":260,"derivative":{"underlying":"Common Stock","underlying_shares":261},"source":{"system":"sec-edgar","filing":"0001104659-20-000881","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000110465920000881/a4.xml","form_type":"4"}},{"id":3323234,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-01-03T16:15:33.000Z","date":"2020-01-03","kind":"tax_withholding","acquired":false,"shares":116,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting person is reporting the withholding by Trovagene, Inc. of 116 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 2, 2020."}],"balance_after":6376,"source":{"system":"sec-edgar","filing":"0001104659-20-000881","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000110465920000881/a4.xml","form_type":"4"}},{"id":3323233,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-01-03T16:15:33.000Z","date":"2020-01-02","kind":"exercise","acquired":true,"shares":261,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the conversion upon vesting of restricted stock units into common stock (the \"Converted Common Stock\").  On January 4, 2017, the reporting person was granted 1,459 restricted stock units, 261 of which vested on January 2, 2020.  Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 4, 2017."}],"balance_after":6492,"source":{"system":"sec-edgar","filing":"0001104659-20-000881","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000110465920000881/a4.xml","form_type":"4"}},{"id":3323230,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2020-01-03T16:10:32.000Z","date":"2020-01-01","kind":"exercise","acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on January 1, 2020. The common stock into which such vested restricted stock units converted on January 1, 2020 is reported in Table I on this Form 4."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on January 1, 2020. The common stock into which such vested restricted stock units converted on January 1, 2020 is reported in Table I on this Form 4."}],"balance_after":521,"derivative":{"underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001104659-20-000872","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000110465920000872/a4.xml","form_type":"4"}},{"id":3323229,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-01-03T16:10:32.000Z","date":"2020-01-03","kind":"tax_withholding","acquired":false,"shares":552,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting person is reporting the withholding by Trovagene, Inc. of 552 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January l, 2020."}],"balance_after":6231,"source":{"system":"sec-edgar","filing":"0001104659-20-000872","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000110465920000872/a4.xml","form_type":"4"}},{"id":3323228,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-01-03T16:10:32.000Z","date":"2020-01-01","kind":"exercise","acquired":true,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the conversion upon vesting of restricted stock units into common stock (the \"Converted Common Stock\").  On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on January 1, 2020.  Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on July 26, 2018."}],"balance_after":6783,"source":{"system":"sec-edgar","filing":"0001104659-20-000872","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000110465920000872/a4.xml","form_type":"4"}},{"id":3398582,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2019-10-03T16:16:34.000Z","date":"2019-10-01","kind":"exercise","acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on October 1, 2019. The common stock into which such vested restricted stock units converted on October 1, 2019 is reported in Table I on this Form 4."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on October 1, 2019. The common stock into which such vested restricted stock units converted on October 1, 2019 is reported in Table I on this Form 4."}],"balance_after":1771,"derivative":{"underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001104659-19-052973","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000110465919052973/a4.xml","form_type":"4"}},{"id":3398581,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-10-03T16:16:34.000Z","date":"2019-10-01","kind":"tax_withholding","acquired":false,"shares":466,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting person is reporting the withholding by Trovagene, Inc. of 466 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on October l, 2019."}],"balance_after":5533,"source":{"system":"sec-edgar","filing":"0001104659-19-052973","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000110465919052973/a4.xml","form_type":"4"}},{"id":3398580,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-10-03T16:16:34.000Z","date":"2019-10-01","kind":"exercise","acquired":true,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the conversion upon vesting of restricted stock units into common stock (the \"Converted Common Stock\").  On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on October 1, 2019.  Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on July 26, 2018."}],"balance_after":5999,"source":{"system":"sec-edgar","filing":"0001104659-19-052973","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000110465919052973/a4.xml","form_type":"4"}},{"id":3468066,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2019-07-03T06:21:34.000Z","date":"2019-07-01","kind":"exercise","acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on July 1, 2019. The common stock into which such vested restricted stock units converted on July 1, 2019 is reported in Table I on this Form 4."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on July 1, 2019. The common stock into which such vested restricted stock units converted on July 1, 2019 is reported in Table I on this Form 4."}],"balance_after":3021,"derivative":{"underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0000899243-19-019005","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000089924319019005/doc4.xml","form_type":"4"}},{"id":3468065,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-07-03T06:21:34.000Z","date":"2019-07-01","kind":"tax_withholding","acquired":false,"shares":461,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting person is reporting the withholding by Trovagene, Inc. of 461 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on July l, 2019."}],"balance_after":4749,"source":{"system":"sec-edgar","filing":"0000899243-19-019005","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000089924319019005/doc4.xml","form_type":"4"}},{"id":3468064,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-07-03T06:21:34.000Z","date":"2019-07-01","kind":"exercise","acquired":true,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the conversion upon vesting of restricted stock units into common stock (the \"Converted Common Stock\").  On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on July 1, 2019.  Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on July 26, 2018."}],"balance_after":5210,"source":{"system":"sec-edgar","filing":"0000899243-19-019005","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000089924319019005/doc4.xml","form_type":"4"}},{"id":3480133,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options","published_at":"2019-06-24T16:06:38.000Z","date":"2019-06-20","kind":"grant","acquired":true,"shares":134203,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"44,734 vest on each of 6/20/2020 and 2021 and 44,735 vest on 6/20/2022"}],"balance_after":158959,"derivative":{"exercise_price":2.48,"expiration_date":"2029-06-20","underlying":"Common Stock","underlying_shares":134203},"source":{"system":"sec-edgar","filing":"0000899243-19-017920","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000089924319017920/doc4.xml","form_type":"4"}},{"id":3565013,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2019-04-03T16:00:28.000Z","date":"2019-04-01","kind":"exercise","acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on April 1, 2019. The common stock into which such vested restricted stock units converted on April 1, 2019 is reported in Table I on this Form 4."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on April 1, 2019. The common stock into which such vested restricted stock units converted on April 1, 2019 is reported in Table I on this Form 4."}],"balance_after":4271,"derivative":{"underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0000899243-19-009746","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000089924319009746/doc4.xml","form_type":"4"}},{"id":3565012,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-04-03T16:00:28.000Z","date":"2019-04-01","kind":"tax_withholding","acquired":false,"shares":459,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting person is reporting the withholding by Trovagene, Inc. of 459 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on April 1, 2019."}],"balance_after":3960,"source":{"system":"sec-edgar","filing":"0000899243-19-009746","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000089924319009746/doc4.xml","form_type":"4"}},{"id":3565011,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-04-03T16:00:28.000Z","date":"2019-04-01","kind":"exercise","acquired":true,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the conversion upon vesting of restricted stock units into common stock (the \"Converted Common Stock\").  On July 24, 2018, the reporting person was granted 7,500 restricted stock units, 1,250 of which vested on April 1, 2019.  Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on July 26, 2018."}],"balance_after":4419,"source":{"system":"sec-edgar","filing":"0000899243-19-009746","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000089924319009746/doc4.xml","form_type":"4"}},{"id":3704140,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2019-01-04T16:10:55.000Z","date":"2019-01-02","kind":"exercise","acquired":false,"shares":1563,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 4,2017, the reporting person was granted 6,250 restricted stock units, 1,563 of which vested on January 2, 2019. The common stock into which such vested restricted stock units converted on January 2, 2019 is reported in Table I on this Form 4."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 4,2017, the reporting person was granted 6,250 restricted stock units, 1,563 of which vested on January 2, 2019. The common stock into which such vested restricted stock units converted on January 2, 2019 is reported in Table I on this Form 4."}],"balance_after":33125,"derivative":{"underlying":"Common Stock","underlying_shares":1563},"source":{"system":"sec-edgar","filing":"0000899243-19-000518","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000089924319000518/doc4.xml","form_type":"4"}},{"id":3704139,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-01-04T16:10:55.000Z","date":"2019-01-02","kind":"tax_withholding","acquired":false,"shares":698,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting person is reporting the withholding by Trovagene, Inc. of 698 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 2, 2019."}],"balance_after":19010,"source":{"system":"sec-edgar","filing":"0000899243-19-000518","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000089924319000518/doc4.xml","form_type":"4"}},{"id":3704138,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-01-04T16:10:55.000Z","date":"2019-01-02","kind":"exercise","acquired":true,"shares":1563,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the conversion upon vesting of restricted stock units into common stock (the \"Converted Common Stock\").  On January 4, 2017, the reporting person was granted 6,250 restricted stock units, 1,563 of which vested on January 2, 2019.  Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 4, 2017."}],"balance_after":19708,"source":{"system":"sec-edgar","filing":"0000899243-19-000518","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000089924319000518/doc4.xml","form_type":"4"}},{"id":3704137,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2019-01-04T16:05:39.000Z","date":"2019-01-01","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On July 24, 2018, the reporting person was granted 45,000 restricted stock units, 7,500 of which vested on January 1, 2019. The common stock into which such vested restricted stock units converted on January 1, 2019 is reported in Table I on this Form 4."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On July 24, 2018, the reporting person was granted 45,000 restricted stock units, 7,500 of which vested on January 1, 2019. The common stock into which such vested restricted stock units converted on January 1, 2019 is reported in Table I on this Form 4."}],"balance_after":34688,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0000899243-19-000506","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000089924319000506/doc4.xml","form_type":"4"}},{"id":3704136,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-01-04T16:05:39.000Z","date":"2019-01-01","kind":"tax_withholding","acquired":false,"shares":3035,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting person is reporting the withholding by Trovagene, Inc. of 3,035 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 1, 2019."}],"balance_after":18145,"source":{"system":"sec-edgar","filing":"0000899243-19-000506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000089924319000506/doc4.xml","form_type":"4"}},{"id":3704135,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-01-04T16:05:39.000Z","date":"2019-01-01","kind":"exercise","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the conversion upon vesting of restricted stock units into common stock (the \"Converted Common Stock\").  On July 24, 2018, the reporting person was granted 45,000 restricted stock units, 7,500 of which vested on January 1, 2019.  Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on July 26, 2018."}],"balance_after":21180,"source":{"system":"sec-edgar","filing":"0000899243-19-000506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000089924319000506/doc4.xml","form_type":"4"}},{"id":3798794,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2018-10-03T17:09:54.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On July 24, 2018, the reporting person was granted 45,000 restricted stock units, 7,500 of which vested on October 1, 2018. The common stock into which such vested restricted stock units converted on October 1, 2018 is reported in Table I on this Form 4."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On July 24, 2018, the reporting person was granted 45,000 restricted stock units, 7,500 of which vested on October 1, 2018. The common stock into which such vested restricted stock units converted on October 1, 2018 is reported in Table I on this Form 4."}],"balance_after":42188,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0000899243-18-026063","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000089924318026063/doc4.xml","form_type":"4"}},{"id":3798793,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-10-03T17:09:54.000Z","date":"2018-10-01","kind":"tax_withholding","acquired":false,"shares":2731,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting person is reporting the withholding by Trovagene, Inc. of 2,731 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on October 1, 2018."}],"balance_after":13680,"source":{"system":"sec-edgar","filing":"0000899243-18-026063","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000089924318026063/doc4.xml","form_type":"4"}},{"id":3798792,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-10-03T17:09:54.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the conversion upon vesting of restricted stock units into common stock (the \"Converted Common Stock\").  On July 24, 2018, the reporting person was granted 45,000 restricted stock units, 7,500 of which vested on October 1, 2018.  Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on July 26, 2018."}],"balance_after":16411,"source":{"system":"sec-edgar","filing":"0000899243-18-026063","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000089924318026063/doc4.xml","form_type":"4"}},{"id":3860929,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2018-07-26T16:30:28.000Z","date":"2018-07-24","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"7,500 of the RSUs will vest on each of October 1, 2018, January 1, 2019, April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"7,500 of the RSUs will vest on each of October 1, 2018, January 1, 2019, April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020."}],"balance_after":49688,"derivative":{"underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000899243-18-020661","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000089924318020661/doc4.xml","form_type":"4"}},{"id":4081861,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2018-02-01T16:30:37.000Z","date":"2018-01-30","kind":"exercise","acquired":false,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On April 7, 2017, the reporting person was granted 90,000 restricted stock units, all of which vested on January 30, 2018. The common stock into which such vested restricted stock units converted on January 30, 2018 is reported in Table I on this Form 4."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On April 7, 2017, the reporting person was granted 90,000 restricted stock units, all of which vested on January 30, 2018. The common stock into which such vested restricted stock units converted on January 30, 2018 is reported in Table I on this Form 4."}],"balance_after":56250,"derivative":{"underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0000899243-18-002487","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000089924318002487/doc4.xml","form_type":"4"}},{"id":4081860,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-02-01T16:30:37.000Z","date":"2018-01-30","kind":"tax_withholding","acquired":false,"shares":42930,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting person is reporting the withholding by Trovagene, Inc. of 42,930 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 30, 2018."}],"balance_after":104367,"source":{"system":"sec-edgar","filing":"0000899243-18-002487","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000089924318002487/doc4.xml","form_type":"4"}},{"id":4081859,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-02-01T16:30:37.000Z","date":"2018-01-30","kind":"exercise","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the conversion upon vesting of restricted stock units into common stock (the \"Converted Common Stock\").  On April 7, 2017, the reporting person was granted 90,000 restricted stock units, all of which vested on January 30, 2018.  Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on April 10, 2017."}],"balance_after":147297,"source":{"system":"sec-edgar","filing":"0000899243-18-002487","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000089924318002487/doc4.xml","form_type":"4"}},{"id":4089783,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options","published_at":"2018-01-25T17:01:49.000Z","date":"2018-01-23","kind":"grant","acquired":true,"shares":672189,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"522,189 vest immediately upon grant and 50,000 vest on each of 1/23/2019, 2020 and 2021."}],"balance_after":1782189,"derivative":{"exercise_price":0.3,"expiration_date":"2028-01-23","underlying":"Common Stock","underlying_shares":672189},"source":{"system":"sec-edgar","filing":"0000899243-18-001904","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000089924318001904/doc4.xml","form_type":"4"}},{"id":4107603,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2018-01-04T20:11:22.000Z","date":"2018-01-02","kind":"exercise","acquired":false,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 2, 2017, the reporting person was granted 75,000 restricted stock units, 18,750 of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 2, 2017, the reporting person was granted 75,000 restricted stock units, 18,750 of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4."}],"balance_after":146250,"derivative":{"underlying":"Common Stock","underlying_shares":18750},"source":{"system":"sec-edgar","filing":"0000899243-18-000527","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000089924318000527/doc4a.xml","form_type":"4/A","original_submission_date":"2018-01-04"}},{"id":4107602,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-01-04T20:11:22.000Z","date":"2018-01-02","kind":"tax_withholding","acquired":false,"shares":9558,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting person is reporting the withholding by Trovagene, Inc. of 9,558 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 2, 2018."}],"balance_after":57297,"source":{"system":"sec-edgar","filing":"0000899243-18-000527","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000089924318000527/doc4a.xml","form_type":"4/A","original_submission_date":"2018-01-04"}},{"id":4107601,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-01-04T20:11:22.000Z","date":"2018-01-02","kind":"exercise","acquired":true,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the conversion upon vesting of restricted stock units into common stock (the \"Converted Common Stock\").  On January 2, 2017, the reporting person was granted 75,000 restricted stock units, 18,750 of which vested on January 2, 2018.  Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 4, 2017."}],"balance_after":66855,"source":{"system":"sec-edgar","filing":"0000899243-18-000527","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000089924318000527/doc4a.xml","form_type":"4/A","original_submission_date":"2018-01-04"}},{"id":4107585,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2018-01-04T17:15:31.000Z","date":"2018-01-02","kind":"exercise","acquired":false,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 2, 2017, the reporting person was granted 75,000 restricted stock units, 18,750 of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 2, 2017, the reporting person was granted 75,000 restricted stock units, 18,750 of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4."}],"balance_after":146250,"derivative":{"underlying":"Common Stock","underlying_shares":18750},"source":{"system":"sec-edgar","filing":"0000899243-18-000481","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000089924318000481/doc4.xml","form_type":"4"}},{"id":4107584,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-01-04T17:15:31.000Z","date":"2018-01-02","kind":"tax_withholding","acquired":false,"shares":9558,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting person is reporting the withholding by Trovagene, Inc. of 9,558 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 2, 2018."}],"balance_after":57243,"source":{"system":"sec-edgar","filing":"0000899243-18-000481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000089924318000481/doc4.xml","form_type":"4"}},{"id":4107583,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-01-04T17:15:31.000Z","date":"2018-01-02","kind":"exercise","acquired":true,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the conversion upon vesting of restricted stock units into common stock (the \"Converted Common Stock\").  On January 2, 2017, the reporting person was granted 75,000 restricted stock units, 18,750 of which vested on January 2, 2018.  Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 4, 2017."}],"balance_after":66801,"source":{"system":"sec-edgar","filing":"0000899243-18-000481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000089924318000481/doc4.xml","form_type":"4"}},{"id":4216101,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2017-09-06T20:41:59.000Z","date":"2017-09-02","kind":"exercise","acquired":false,"shares":30001,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 2, 2017, the reporting person was granted 30,001 restricted stock units, all of which vested on September 2, 2017. The common stock into which such vested restricted stock units converted on September 2, 2017 is reported in Table I on this Form 4."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 2, 2017, the reporting person was granted 30,001 restricted stock units, all of which vested on September 2, 2017. The common stock into which such vested restricted stock units converted on September 2, 2017 is reported in Table I on this Form 4."}],"balance_after":165000,"derivative":{"underlying":"Common Stock","underlying_shares":30001},"source":{"system":"sec-edgar","filing":"0001104659-17-055891","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000110465917055891/a4.xml","form_type":"4"}},{"id":4216100,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2017-09-06T20:41:59.000Z","date":"2017-09-02","kind":"tax_withholding","acquired":false,"shares":12928,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting person is reporting the withholding by Trovagene, Inc. of 12,928 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on September 2, 2017."}],"balance_after":48051,"source":{"system":"sec-edgar","filing":"0001104659-17-055891","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000110465917055891/a4.xml","form_type":"4"}},{"id":4216099,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2017-09-06T20:41:59.000Z","date":"2017-09-02","kind":"exercise","acquired":true,"shares":30001,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the conversion upon vesting of restricted stock units into common stock (the \"Converted Common Stock\").  On January 2, 2017, the reporting person was granted 30,001 restricted stock units, all of which vested on September 2, 2017.  Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 4, 2017."}],"balance_after":61033,"source":{"system":"sec-edgar","filing":"0001104659-17-055891","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000110465917055891/a4.xml","form_type":"4"}},{"id":4225591,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options","published_at":"2017-08-24T16:06:34.000Z","date":"2017-08-22","kind":"grant","acquired":true,"shares":385000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"48,125 vest immediately upon grant and 48,125 vest quarterly for 7 quarters following the date of grant."}],"balance_after":1110000,"derivative":{"exercise_price":0.85,"expiration_date":"2027-08-22","underlying":"Common Stock","underlying_shares":385000},"source":{"system":"sec-edgar","filing":"0001104659-17-053434","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000110465917053434/a4.xml","form_type":"4"}},{"id":4355423,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2017-04-10T16:04:01.000Z","date":"2017-04-07","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSU shall vest on January 30, 2018 provided that the reporting person provides continuous service to Trovagene, Inc."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSU shall vest on January 30, 2018 provided that the reporting person provides continuous service to Trovagene, Inc."}],"balance_after":195001,"derivative":{"underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001104659-17-022532","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000110465917022532/a4.xml","form_type":"4"}},{"id":4503034,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2017-01-04T17:01:12.000Z","date":"2017-01-02","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs shall vest in equal annual installments over 4 years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The RSUs shall vest in equal annual installments over 4 years."}],"balance_after":105001,"derivative":{"underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001104659-17-000632","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000110465917000632/a4.xml","form_type":"4"}},{"id":4503033,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2017-01-04T17:01:12.000Z","date":"2017-01-02","kind":"grant","acquired":true,"shares":30001,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSU shall vest on September 2, 2017 provided that the reporting person provides continuous service to Trovagene, Inc."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSU shall vest on September 2, 2017 provided that the reporting person provides continuous service to Trovagene, Inc."}],"balance_after":30001,"derivative":{"underlying":"Common Stock","underlying_shares":30001},"source":{"system":"sec-edgar","filing":"0001104659-17-000632","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000110465917000632/a4.xml","form_type":"4"}},{"id":4503032,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2017-01-04T17:01:12.000Z","date":"2017-01-02","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On May 2, 2016, the reporting person was granted 50,000 restricted stock units, all of which vested on January 2, 2017. The common stock into which such vested restricted stock units converted on January 2, 2017 is reported in Table I on this Form 4."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On May 2, 2016, the reporting person was granted 50,000 restricted stock units, all of which vested on January 2, 2017. The common stock into which such vested restricted stock units converted on January 2, 2017 is reported in Table I on this Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-17-000632","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000110465917000632/a4.xml","form_type":"4"}},{"id":4503031,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2017-01-04T17:01:12.000Z","date":"2017-01-02","kind":"tax_withholding","acquired":false,"shares":23968,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting person is reporting the withholding by Trovagene, Inc. of 23,968 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 2, 2017."}],"balance_after":31032,"source":{"system":"sec-edgar","filing":"0001104659-17-000632","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000110465917000632/a4.xml","form_type":"4"}},{"id":4503030,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2017-01-04T17:01:12.000Z","date":"2017-01-02","kind":"exercise","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the conversion upon vesting of restricted stock units into common stock (the \"Converted Common Stock\").  On May 2, 2016, the reporting person was granted 50,000 restricted stock units, all of which vested on January 2, 2017.  Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on May 4, 2016."}],"balance_after":55000,"source":{"system":"sec-edgar","filing":"0001104659-17-000632","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000110465917000632/a4.xml","form_type":"4"}},{"id":4520669,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":82020,"kind":"person","name":"Erlander Mark","position":1,"cik":"0001651537","reported_name":"Erlander Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2016-12-15T17:00:35.000Z","date":"2016-12-14","kind":"purchase","acquired":true,"shares":5000,"price":2.075,"value":10375.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001104659-16-162330","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651537/000110465916162330/a4.xml","form_type":"4"}}]}